Search 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Novel target discovery. 
•Biotherapeutic (Immunotherapy & ADC) early discovery.
•Biotherapeutic (Immunotherapy & ADC) design and development.
•Intrapreneurship.
•Duties with Pfizer External R&D Innovation & Scouting for novel technologies in therapeutics, diagnostics & medical devices: 
(Screen & evaluate early/mid stage (inter)national biotech/pharma technologies that 
align with Pfizer’s R&D interest/vision & aid with triaging and funding of such technologies toward
corporate strategic partnerships). 
•NYC Bio-entrepreneurship mentor for early stage life science ventures through Pfizer Business 
Development and the New York Economic Development Council (ELabNYC, British Consulate, Columbia University).
•Adjunct Faculty member for National Science Foundation (NSF) I-Corps: 
The NYC Regional Innovation Node (NYCRIN): Bioentrepreneurship ventures.

A clinical research provider that conducts clinical research for pharmaceutical and biotechnological companies as well as government sponsored trials. We also facilitate training programs for clinical research practitioners and site preparation for studies.

We also aim to help clinical research facilities and professionals conduct clinical trials following GCP/ICH. By doing so we believe will be beneficial to pharmaceutical companies as it would allow for clinical trials to run smoother and more efficiently. It will also help subjects get quality service during the clinical studies.

Donec sodales a quam in imperdiet. Aliquam massa libero, malesuada nec interdum sit amet, gravida quis nibh. Praesent facilisis tristique egestas. Curabitur vitae metus vitae libero iaculis suscipit. Nullam non velit metus. Curabitur at euismod felis. Aenean viverra sem sit amet ante bibendum, sit amet vehicula eros dapibus.

We build financial products so you can participate in the healthcare and life science economy. Companies, investors, consumers and entrepreneurs will have access to financial products to create and/or manage their financial exposure to healthcare and the life science sector.

Poliwogg's management team has extensive experience in finance, healthcare, foundations, government and investing. It combines that expertise with a passion for increasing and broadening investment in healthcare, the largest sector of the American economy.

At Precision for Medicine, we specialize in accelerating the development, approval and launch of complex or first-in-class medical technologies.  We work regularly with medical device, diagnostics and life sciences companies as well as with investors in this space.  We have expert teams in each of regulatory affairs, biostatistics and analytics, clinical trial services, commercial strategy and market access/reimbursement.  Our experts work within and across these verticals to develop the latest techniques for product success.  

Core services include:

To-Market Strategy, a collaborative effort to manage risk and maximize opportunity at each stage of product development 

Due Diligence and Opportunity Assessments, to inform potential investments or new areas of product development

Regulatory Strategy and Support, including U.S. FDA, E.U. and global regulatory stratgies, negotitations and submissions

Evidence Development Strategy, including advanced non-clinical and clinical trial designs, statistical analysis plans, and literature-based approaches

Clinical Trial Services, from study start through conclusion and reporting

KOL Recruitment and management of key clinical advisors (CABs, SABs, KOLs, expert panels and reports, study investigators, etc.)

Market Access Services, including payer communications, reimbursement strategy, and health economics

Personalized Medicine Strategies, including responder analyses, companion diagnostics and biomarker identification 

Digital Medicine Strategy, including software-based products and accessory apps

Business Strategy, including business model ideation, market research, due diligence and fundraising support

oronary Artery Disease (CAD) is the leading cause of death worldwide, accounting for over 7 Million deaths annually — more than any other disease category.

Premier Heart's Multifunction Cardiogram is the only non-invasive online diagnostic testing tool designed to assist physicians in quickly and accurately detecting heart diseases, including CAD ischemia.
When compared to traditional methods MCG has consistently been able to more accurately detect ischemia at earlier stages, enabling physicians to intervene and save lives.

The results from MCG have been validated in double-blind clinical studies where our system has demonstrated accuracy comparable to coronary angiography (90% overall sensitivity, 85% specificity).
This level of accuracy results from advanced techniques in signal processing and systems analysis combined with our unmatched clinical database which allows MCG to provide quantitative, evidence-based results to assist in reaching a diagnosis.

We invite you to review our clinical trial results, user endorsements and technical data. If you want to learn more about using MCG in your practice or would like more information about our technology please feel free to contact us.

Proception in-licenses Medtech IP, improves the IP, develops the products, gains regulatory approval, gains clinical experience and then out-licenses the product to a large medical device company using a unique out-licensing model.

Provid Pharmaceuticals Inc. was founded to discover novel therapeutics for autoimmune diseases using peptide mimetics technology.   Provid’s strategy has resulted in the discovery of PV-267, a small molecule drug candidate for the treatment of multiple sclerosis (MS) and leads for rheumatoid arthritis and other autoimmune diseases that operate by blocking disease-associated MHC class II molecules.

Provid’s MS drug candidate, PV-267 uniquely inhibits the MHC Class II molecule HLA-DR2b, the most important gene target in the autoimmune disease process in MS.  MS is genetically linked with HLA-DR2b (DRB1*1501).  DR2b is carried by a majority of MS patients (ca. 700,000 worldwide) and binds and presents antigenic myelin fragments to autoreactive T cells, triggering the autoimmune response that damages myelin insulation on nerves, leading to MS disease symptoms and disability.  Provid designed PV-267 to bind tightly and selectively to DR2b, blocking antigen binding.  PV-267 has been shown to disrupt the autoimmune process in MS animal models and in human cells from DR2+ patients.  Because PV-267 does not compromise other aspects of the immune system, its potential for superior safety is a major advantage over current disease-modifying drugs.

Recent data have shown that PV-267 has high oral bioavailability in a proprietary formulation being developed in collaboration with Enteris Biopharma.  Oral efficacy, while not essential to test the concept of the DR2 inhibitory mechanism, is an important factor commercially and for the MS patient.

Early Clinical Trial Concept.  Because of its DR2b antagonist mechanism, it is feasible to assess immunological efficacy in DR2b+ individuals in early clinical trials, greatly reducing the clinical development risk and clearing the path for a targeted phase II efficacy trial.  These studies are being planned by our Clinical Advisory Board under the leadership of Prof. Larry Steinman at Stanford. 

Development Plan. Provid will pursue preclinical and early clinical studies of our DR2b inhibitors and is seeking partnerships with pharma company partners.

The mission of PTM Biolabs is to address the unmet needs for life sciences and personalized medicine, by the creation and supply of innovative technologies in the fields of biological reagents, proteomics, and diagnostics.

Founded in 2010, PTM Biolabs has become the leading powerhouse for the following technologies:

• High-quality antibodies targeting specific PTM pathways and epigenetic code;
• High-sensitivity proteomic services for biopharmaceutical research and development.

Our products and services have been profoundly expediting the understanding in the fields of protein post translational modifications (PTMs), epigenetics, drug target screening and biomarker discovery.

Together, we empower the future by epigenetics and proteomics!

We are an organization founded by scientists, built on solid science and driven by continuous innovation. Our keen devotion to scientific discoveries is demonstrated by rich history of publications in renowned scientific journals.

We lay the corporation corner stone on technological advancements. Ever since our inception, disruptive technologies have been developed from our bench, delivered to scientists and engineers worldwide, and kept benefiting the research activities, both academia and industry.

We strive for continuous quality improvement in all that we do, how we do it, and what we deliver! We have built a tracking record in service excellence and product quality, which showcases the respectful recognization by customers, employees and the community.

We practice the highest ethical standards and honor our commitments. We take profound responsibility for each and every step of our actions, and treat everyone fairly with trust and respect.

Satisfied customers are essential to our success. We achieve total customer satisfaction by listening to your specific needs, addressing the issues with our expertise and finally delivering the results toward your success.

We value the skills, strengths, and perspectives of our diverse team. We foster a workplace that enables people to get involved in making decisions about their work that advance our common objectives.

We provide a safe workplace and protect the environment. We promote the health and well-being of people and their families. We work with our communities by volunteering and supporting worthy causes.